For Immediate Release

CiNTL Pharma B.V. Unveils CiNTL.AI to Revolutionize Pre-Clinical Market Access Identification for Phase 1-4 Clinical Trials

September 15, 2024

Leiden, The Netherlands, September 15, 2024 – CiNTL Pharma B.V. is excited to introduce CiNTL.AI, an innovative solution designed to enhance pre-clinical market access identification for Phase 1-4 clinical trials. This cutting-edge technology leverages Artificial Intelligence (AI) and Machine Learning (ML) to streamline trial feasibility, optimize site selection, and accelerate drug development timelines.

“The complexities of clinical trials demand a smarter, data-driven approach to market access identification,” said Yolanda Cabrera-Sybesma, Chief Executive Officer of CiNTL Pharma B.V. “With CiNTL.AI, we are equipping pharmaceutical and biotechnology companies with real-time insights that will enable them to make informed decisions at every phase of clinical research, ensuring faster and more efficient trial execution.”

CiNTL.AI is designed to address critical challenges in early-stage market access, such as identifying suitable patient populations, evaluating regulatory landscapes, and assessing competitive positioning. By integrating advanced analytics, the platform empowers researchers to mitigate risks, reduce costs, and enhance the overall success rates of clinical trials.

“With CiNTL.AI, we are bridging the gap between data science and clinical research, enabling life sciences companies to proactively address market access barriers from the earliest trial stages,” added Cabrera-Sybesma. “By leveraging AI, we can drive efficiency, reduce uncertainty, and accelerate the availability of life-saving treatments.”

For more information about CiNTL Pharma B.V. and its commitment to AI-driven clinical research innovation, visit www.cintlpharma.com.

CiNTL Pharma B.V. is a Contract Research Organization (CRO) that provides clinical research development, consultancy and data driven solution services to the pharmaceutical, biotechnology and life sciences industries.

For media inquiries, partnerships, or collaborations, please contact CiNTL Pharma Business Development at BD@cintlpharma.com.

Witness the future of intelligent clinical research – Experience CiNTL Pharma today.